Overview of the drug development pipeline for endometrial cancer
It has been observed that endometrial cancer is a type of uterine cancer, which begins in the layer of cells that form the lining (endometrium) of the uterus of women. Unopposed endometrial estrogen exposure such as estrogen replacement therapy during menopause is associated with increased risk of developing endometrial cancer among women. Endometrial cancer is traditionally divided into estrogen-dependent (type I) and estrogen-independent (type II). Type II tumors are generally less well differentiated and have poorer prognoses than type I tumors, and they account for a disproportionate number of endometrial cancer deaths. Monotherapy is emerging to be the most efficient approach for the treatment of endometrial cancer.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for endometrial cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Get a free sample of this report now!
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of endometrial cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- AbbVie
- AstraZeneca
- Bristol-Myers Squibb
Therapeutic assessment of the drug development pipeline for endometrial cancer by route of administration
- Intravenous
- Oral
- Intradermal
- Intramuscular
- Undisclosed
The intravenous route of administration (ROA) involves the application of the drug directly into the veins and in the oral technique, the molecules are delivered through the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for endometrial cancer by therapy
- Monotherapy
- Combination therapy
- Monotherapy/combination therapy
- Undisclosed
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for endometrial cancer are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for endometrial cancer?
- What are the companies that are currently involved in the development of drug molecules for endometrial cancer?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.